In the last few years, the development of targeted therapies for non-small cell lung cancer
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …

With the development of precision medicine, molecular targeted therapy has been widely
used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal …

Epidermal growth factor receptor (EGFR) mutations (EGFRm+) occur in 10–35% of non-
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …

Gefitinib and erlotinib are ATP competitive inhibitors of the epidermal growth factor receptor
(EGFR) tyrosine kinase and are approved around the world for the treatment of patients with …

Gefitinib and erlotinib, which are epidermal growth factor receptor‐(EGFR‐) specific tyrosine
kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non‐small‐cell …

Patients with EGFR-mutant lung cancer derive significant therapeutic benefit from treatment
with EGFR tyrosine kinase inhibitors (TKI). Unfortunately, acquired resistance is an …

The EGFR has been targeted through the development of selective tyrosine kinase inhibitors
(TKIs) that have proven effective in a subset of non-small cell lung cancer (NSCLC) patients …

Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when
administered individually or in combination to non-small cell lung cancer (NSCLC) patients …

Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …

Epidermal growth factor receptor (EGFR) mutations act as oncogenic drivers in the cellular
signal transduction pathway and induce downstream activation of several key cellular …